| Bioactivity | ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist, with EC50 values of 7.12 nM, 517 nM for hS1P1 and hS1P3, respectively. ASP1126 decreases the number of peripheral lymphocytes, naive T cells, central memory T cells and effector memory T cells in the peripheral blood. ASP1126 has the potential to be applied in clinical transplantation with improved safety profile[1]. |
| Target | EC50: 7.12 nM (hS1P1), 517 nM (hS1P3). |
| In Vivo | ASP1126 (1 and 5 mg/kg, orally once daily for 14 days) significantly prolongs allograft survival[1].ASP1126 in combination with 0.02 mg/kg tacrolimus notably improves graft survival time[1]. Animal Model: |
| Name | ASP1126 |
| CAS | 1228580-11-7 |
| Formula | C26H26ClF6NO5 |
| Molar Mass | 581.93 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Okimoto A, et al. ASP1126, a Novel Sphingosine-1-Phosphate-Selective Agonist With a Favorable Safety Profile, Prolongs Allograft Survival in Rats and Nonhuman Primates in Combination With Tacrolimus With a Broad Safety Margin for Bradycardia. Transplant P |
ASP1126
CAS: 1228580-11-7 F: C26H26ClF6NO5 W: 581.93
ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist, with EC50 values of 7.12 nM, 517 nM for
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.